Panacea Index Logo

Command Palette

Search for a command to run...

European guideline for the diagnosis and treatment of insomnia.

Journal of sleep research
December 1, 2017
Dieter Riemann et al. (27 authors)
Journal ArticlePractice GuidelineHuman StudyClinical
Study Details

Study Goal

The researchers aimed to evaluate the usefulness of light therapy in the treatment of insomnia.

Results Summary

The study found that light therapy needs further evaluation to determine its effectiveness for insomnia treatment, with weak recommendations and low-quality evidence supporting its use.

Population

Adults with chronic insomnia disorder.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (9)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Cognitive behavioural therapy for insomnia
no change
chronic insomnia
adults of any age
-
recommended as the first-line treatment
#1
Benzodiazepines, benzodiazepine receptor agonists and some antidepressants
decrease
insomnia
-
short-term treatment (≤4 weeks)
effective
#2
Antihistamines
no change
insomnia treatment
-
-
not recommended
#3
Antipsychotics
no change
insomnia treatment
-
-
not recommended
#4
Melatonin
no change
insomnia treatment
-
-
not recommended
#5
Phytotherapeutics
no change
insomnia treatment
-
-
not recommended
#6
Light therapy
no change
usefulness in the treatment of insomnia
-
-
need to be further evaluated
#7
Exercise
no change
usefulness in the treatment of insomnia
-
-
need to be further evaluated
#8
Complementary and alternative treatments (e.g. homeopathy, acupuncture)
no change
insomnia treatment
-
-
not recommended
#9
Abstract

This European guideline for the diagnosis and treatment of insomnia was developed by a task force of the European Sleep Research Society, with the aim of providing clinical recommendations for the management of adult patients with insomnia. The guideline is based on a systematic review of relevant meta-analyses published till June 2016. The target audience for this guideline includes all clinicians involved in the management of insomnia, and the target patient population includes adults with chronic insomnia disorder. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system was used to grade the evidence and guide recommendations. The diagnostic procedure for insomnia, and its co-morbidities, should include a clinical interview consisting of a sleep history (sleep habits, sleep environment, work schedules, circadian factors), the use of sleep questionnaires and sleep diaries, questions about somatic and mental health, a physical examination and additional measures if indicated (i.e. blood tests, electrocardiogram, electroencephalogram; strong recommendation, moderate- to high-quality evidence). Polysomnography can be used to evaluate other sleep disorders if suspected (i.e. periodic limb movement disorder, sleep-related breathing disorders), in treatment-resistant insomnia, for professional at-risk populations and when substantial sleep state misperception is suspected (strong recommendation, high-quality evidence). Cognitive behavioural therapy for insomnia is recommended as the first-line treatment for chronic insomnia in adults of any age (strong recommendation, high-quality evidence). A pharmacological intervention can be offered if cognitive behavioural therapy for insomnia is not sufficiently effective or not available. Benzodiazepines, benzodiazepine receptor agonists and some antidepressants are effective in the short-term treatment of insomnia (≤4 weeks; weak recommendation, moderate-quality evidence). Antihistamines, antipsychotics, melatonin and phytotherapeutics are not recommended for insomnia treatment (strong to weak recommendations, low- to very-low-quality evidence). Light therapy and exercise need to be further evaluated to judge their usefulness in the treatment of insomnia (weak recommendation, low-quality evidence). Complementary and alternative treatments (e.g. homeopathy, acupuncture) are not recommended for insomnia treatment (weak recommendation, very-low-quality evidence).

Medical Subject Headings (MeSH)
AdultAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesCognitive Behavioral TherapyComorbidityComplementary TherapiesEuropeFemaleHistamine AntagonistsHumansMaleMelatoninPhototherapyPolysomnographySleepSleep Initiation and Maintenance Disorders
Study Links
Quality Scores
SafetyNot Assessed
Efficacy30/10
Quality75/10
Citation Metrics
Total Citations1,152
Citations/Year144.0
Relative Citation Ratio67.72
NIH Percentile100%
Research Impact Scores
APT Score0.95
Weight Score2.50
Normalized Score0.47
Related Supplements